Acute Coronary Syndrome

Type: Keyphrase
Name: Acute Coronary Syndrome
First reported 5 hours ago - Updated 5 hours ago - 1 reports

On The Pulse - 19th September 2014

Flu vaccination in pregnancyAlthough pregnant women are particularly susceptible to seasonal influenza, vaccination may not be as effective as in non-pregnant women, because immune responses are attenuated in pregnancy. Further, if the pregnant woman ... [Published OnMedicanet - 5 hours ago]
First reported 18 hours ago - Updated 18 hours ago - 1 reports

Waterford service affected by lack of consultants

It is a challenge to maintain the critical mass of consultants to deliver the Waterford cardiology service “in a high quality and safe manner”, the HSE has accepted.Having an adequate number of consultants to provide the service was proving a challenge ... [Published Irish Medical Times - 18 hours ago]
First reported Sep 15 2014 - Updated Sep 16 2014 - 8 reports

Alirocumab Acute Coronary Syndrome Market Analysis & Forecasts to 2023

Dallas, TX -- (SBWIRE) -- 09/16/2014 -- “Zontivity (Acute Coronary Syndrome) Forecast and Market Analysis to 2023?. The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care ... [Published CEOWorld Magazine - Sep 16 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 2 reports

ACCA congress: Ensuring a rapid response to cardiac emergencies

Acute Cardiovascular Care 2014 is the event of the year for the latest science in the field. It is the annual meeting of the Acute Cardiovascular Care Association (ACCA) of the European Society of Cardiology (ESC) and takes place 18-20 October in Geneva, ... [Published Bio-Medicine - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

High-Risk Plaque on CCTA Predicts ACS in Acute Chest Pain

Goldstein JA, Chinnaiyan KM, Abidov A, et al. The CT-STAT (Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment) trial. J Am Coll Cardiol 2011;58:1414–22.Hoffmann U, Truong QA, Schoenfeld DA, et al. ... [Published General Medicine eJournal - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Interrelationships between ALOX5AP Polymorphisms, Serum Leukotriene B4 Level and Risk of Acute Coronary Syndrome

by Guoping He, Shan Ye, Jingjiao Hui, Dandan Shen, Chuanping Qi, Lianhong Xu, Yichao QianBackgroundWe investigated the relationships between the ALOX5AP gene rs10507391 and rs4769874 polymorphisms, serum levels of leukotriene (LT) B4, and risk of acute ... [Published Plosone.org - Sep 12 2014]
First reported Sep 10 2014 - Updated Sep 11 2014 - 2 reports

Inhibiting inflammatory enzyme after heart attack does not reduce risk of subsequent event

By a News Reporter-Staff News Editor at Biotech Week -- In patients who experienced an acute coronary syndrome (ACS) event (such as heart attack or unstable angina), use of the drug darapladib to inhibit the ... ... [Published Town Hall - Sep 11 2014]
First reported Sep 07 2014 - Updated Sep 07 2014 - 4 reports

Cangrelor Acute Coronary Syndrome Industry (Antithrombotics, Antihypertensives & Statins) Analysis & Forecasts to 2023

DALLASPhoto - http://photos.prnewswire.com/prnh/20140905/143413The Medicines Company's co-promotion of Brilinta began in the US in 2012. AstraZeneca's role in marketing cangrelor, if and when it is approved, is unclear. According to the 2003 acquisition ... [Published Bio-Medicine - Sep 07 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 2 reports

NICE: New guidelines for heart attack treatments

New guidelines for improving diagnosis and treatment of unstable angina and heart attacks have been released by the National Institute of Health and Care Excellence (NICE).Six new quality statements from NICE lay out the importance of treating heart attack ... [Published Nursing In Practice - Sep 05 2014]
First reported Aug 31 2014 - Updated Sep 01 2014 - 3 reports

Bayer HealthCare launches three new studies of Xarelto

:24 in Pharmaceutical Company Product News Bayer HealthCare has announced a new expansion of the global clinical development programme for Xarelto, its rivaroxaban-based oral Factor Xa inhibitor therapy. The three new studies will assess the safety and ... [Published Zenopa - Sep 01 2014]
First reported Aug 31 2014 - Updated Sep 01 2014 - 2 reports

Resistant hypertension increases stroke risk by 35% in women and 20% in elderly Taiwanese

: Resistant hypertension increases the risk of stroke by 35% in women and 20% in elderly Taiwanese patients, according to research presented at ESC Congress today by Dr Kuo-Yang Wang from Taiwan. The findings suggest that gender and age should be added ... [Published European Society of Cardiology - Aug 31 2014]
First reported Aug 20 2014 - Updated Aug 21 2014 - 2 reports

AstraZeneca: DoJ Closes Investigation into PLATO Clinical Trial for BRILINTA [Health & Beauty Close - Up]

AstraZeneca said that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA (ticagrelor) tablets.The government is not planning any further action, the ... [Published Pharmacy Choice - Aug 21 2014]

Quotes

"There has definitely been more uptake of these more potent antiplatelet therapies," added Wang. "In the US, a lot of it is driven by socioeconomic factors"
...According to news reporting from Wiesbaden, Germany , by NewsRx editors, the research stated, "Reticulated platelets are immature platelets circulating in blood; they reflect the activity of megakaryopoiesis in the bone marrow. Therefore, they can be used as a non-invasive test in patients with thrombocytopenia in various clinical conditions."
...one important factor," study senior author William Shrank, senior vice president and chief scientific officer at CVS Health, said in a statement. "This study provides clear evidence that the use of lower-cost generic medications, when appropriate, not only reduces cost for the patient and improves adherence, but also improves health and reduces mortality."
...Professor Maddalena Lettino, chair of the congress programme committee, said: "Original data focused on acute patients will be presented in a top level forum by researchers from across the globe."

More Content

All (291) | News (246) | Reports (0) | Blogs (40) | Audio/Video (0) | Fact Sheets (2) | Press Releases (2)
sort by: Date | Relevance
On The Pulse - 19th September 2014 [Published OnMedicanet - 5 hours ago]
Niacin With Statins? No Dice. [Published Theheart.org - 8 hours ago]
TRANSLATE-ACS: No MACE Benefit With Prasugrel i... [Published American Journal of Public Health - 18 hours ago]
Waterford service affected by lack of consultants [Published Irish Medical Times - 18 hours ago]
Researchers at Abbott Target Thrombocytopenia (... [Published HispanicBusiness.com - Sep 17 2014]
Generic Statins are More Effective than Brand-N... [Published Boston Magazine - Sep 17 2014]
Hospital wins national award [Published Grand Rapids Business Journal - Sep 17 2014]
3 http://www.amarincorp.com/productsale.html 63... [Published Student Village - Sep 17 2014]
TCT.14: Women interventionalists few but proced... [Published Cardiovascular Business - Sep 17 2014]
CVS study: Starting therapy with a generic impr... [Published Chain Drug Review - Sep 16 2014]
Alirocumab Acute Coronary Syndrome Market Analy... [Published CEOWorld Magazine - Sep 16 2014]
CVS Health study shows improved adherence and o... [Published Drug Store News - Sep 16 2014]
Alirocumab (Acute Coronary Syndrome) - Forecast... [Published Stock Nod - Sep 16 2014]
Zontivity (Acute Coronary Syndrome) - Forecast ... [Published Stock Nod - Sep 16 2014]
ACCA congress: Ensuring a rapid response to car... [Published Bio-Medicine - Sep 16 2014]
ACCA congress: Ensuring a rapid response to car... [Published EurekAlert! - Sep 16 2014]
Brilinta Market (Acute Coronary Syndrome) Marke... [Published MyNewsDesk - Sep 16 2014]
Comparative Effectiveness of Generic and Brand-... [Published Annals of Internal Medicine - Sep 16 2014]
Cheaper Generic Statins Beat Brand-Name Statins... [Published Forbes.com - Sep 15 2014]
Generics Beat Brand-Name Statins for Patient Ad... [Published Diabetes Care - Sep 15 2014]
What's more effective: Generic or brand-name st... [Published Medical Xpress - Sep 15 2014]
Reassuring Data on Use of DAPT and Anticoagulation [Published General Medicine eJournal - Sep 15 2014]
Research and Markets: Brilinta (Acute Coronary ... [Published Fort Mills Times - Sep 15 2014]
Research and Markets: Brilinta (Acute Coronary ... [Published Business Wire Health News - Sep 15 2014]
Research and Markets: Brilinta (Acute Coronary ... [Published Industrial Info Financials - Sep 15 2014]
Brilinta (Acute Coronary Syndrome) - Forecast a... [Published Individual.com - Sep 15 2014]
High-Risk Plaque on CCTA Predicts ACS in Acute ... [Published General Medicine eJournal - Sep 15 2014]
Interrelationships between ALOX5AP Polymorphism... [Published Plosone.org - Sep 12 2014]
Clinical Review: Hypothyroidism [Published GP Online - Sep 12 2014]
Unique Antibody Responses to Malondialdehyde-Ac... [Published Plosone.org - Sep 11 2014]
1 2 3 4 5 6 7 8 9 10
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Research and Markets: Brilinta (Acute Coronary ... [Published Business Wire Health News - Sep 15 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jdv9kp/brilinta_acute) has announced the addition of the "Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023" report to their offering. The ...
Cangrelor Acute Coronary Syndrome Industry (Ant... [Published PR Newswire: General Business - Sep 07 2014]
DALLAS, Sept. 7, 2014 /PRNewswire-iReach/ -- New PharmaPoint Drug Evaluation report, "Cangrelor (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023". The current ACS market – primarily comprised of antithrombotics, antihypertensives, ...
US Acute Coronary Syndrome Drugs Industry (Anti... [Published PR Newswire: General Business - Sep 07 2014]
DALLAS, September 7, 2014 /PRNewswire/ --MarketOptimizer.org adds "Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023", a new research report to its store. Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology ...
ESC: Darapladib Fails in ACS Trial (CME/CE) [Published MedPageToday.com - medical news plus CME for ph ... - Aug 31 2014]
BARCELONA (MedPage Today) -- Inhibiting an enzyme involved in inflammation has once again failed to reduce cardiovascular events, this time in patients who had been hospitalized with an acute coronary syndrome event, researchers reported here. ...
Top stories in health and medicine, August 20, ... [Published KevinMD.com - Aug 20 2014]
From  MedPage Today : Moving Target for BP Guidelines . The current blood pressure target recommendations may need to be revisited in hypertensive patients with coronary artery disease who are 60 years and older. Transcatheter Mitral Valve Repair ...
1 2 3 4 5 6 7 8

Press Releases

sort by: Date | Relevance
Regado Biosciences Announces $20 Million Privat... [Published PR Newswire - Jan 31 2014]
The Acute Coronary Syndrome 12-Month Posthospit... [Published PR Newswire - Dec 11 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.